Combined corneal biomechanical and tomographical indices in subclinical and forme fruste keratoconus.

Indian J Ophthalmol

Dr. Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS Campus Temple, Sri Aurobindo Marg, Ansari Nagar East, New Delhi, Delhi, India.

Published: September 2024

Purpose: Evaluation of combined corneal tomographic and biomechanical parameters in subclinical/forme fruste keratoconus (ScKC/FFKC).

Design: Cross-sectional observational case-control study.

Methods Inclusion Criteria: Thirty-one eyes with ScKC (fellow eye of KC with any one sign: keratometry >47 diopters, cylinder >1.5 D, central corneal thickness <500 µm, with/without abnormal topography) or FFKC (fellow eye of KC with normal topography and slit lamp examination) >13 years (cases) and 44 eyes of age-matched 22 healthy subjects (controls).

Exclusion Criteria: Clinically diagnosed KC, presence of corneal scars, and prior ocular surgery eyes.

Study Parameters: Sixteen Pentacam, 15 Corvis ST, and five Sirius parameters were analyzed using paired sample t -test, and a subsample found to be significantly different was used in receiver operating characteristic curve analysis. The Youden index was calculated, and Pearson's correlation analysis was done.

Results: Five Pentacam, three Corvis ST, and two Sirius parameters had an area under curve (AUC) >0.75. Tomographic and biomechanical index (TBI) (cutoff 0.59, 95% specificity, 77% sensitivity), Belin Ambrosio enhanced ecstasia display (cutoff 1.8, 81% specificity, 80% sensitivity), and symmetry index of posterior corneal curvature (cutoff 0.16, 97% specificity, 67% sensitivity) best identified early KC. TBI strongly correlated with maximum Pentacam parameters in both cases and controls. Corvis biomechanical index strongly correlated only in cases, and SP-A1-SD weakly correlated in cases.

Conclusion: Upon combined analysis, the average sensitivity and specificity, respectively, of top three parameters (according to AUC) from Pentacam and Corvis ST were 74.1% and 95.4% for posterior elevation and TBI.

Trial Registration: The trial was registered in Clinical Trial Registry of India on January 28, 2022. The Trial Registration Number is REF/2022/01/050638.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552823PMC
http://dx.doi.org/10.4103/IJO.IJO_766_24DOI Listing

Publication Analysis

Top Keywords

combined corneal
8
fruste keratoconus
8
tomographic biomechanical
8
pentacam corvis
8
corvis sirius
8
sirius parameters
8
parameters
6
biomechanical
4
corneal biomechanical
4
biomechanical tomographical
4

Similar Publications

Association of Blood Pressure and Retinal Nerve Fiber Layer Rates of Thinning in Patients with Moderate to Advanced Glaucoma.

Ophthalmol Glaucoma

January 2025

Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. Electronic address:

Purpose: Investigate the influence of baseline blood pressure (BP) on retinal nerve fiber layer (RNFL) rates of change (RoC) in glaucoma patients with central damage or moderate to severe disease.

Design: Prospective cohort study.

Participants: 110 eyes with ≥4 RNFL optical coherence tomography scans and ≥2 years of follow-up.

View Article and Find Full Text PDF

Topical Netarsudil in Childhood Glaucoma: A Systematic Review.

Curr Eye Res

January 2025

Department of Ophthalmology, Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Purpose: To evaluate the effectiveness and safety of topical netarsudil 0.02% in managing childhood glaucoma.

Methods: A literature search in the electronic databases of PubMed CENTRAL, Google Scholar, EMBASE, the Register of Controlled Trials, and Ovid MEDLINE from January 2017 to August 2023 using one or a combination of the following terms: "netarsudil," "rhopressa," "Rho-kinase," "pediatric glaucoma," "childhood glaucoma," "intraocular pressure" was conducted.

View Article and Find Full Text PDF

Background: Acanthamoeba keratitis (AK) is the most challenging corneal infection to treat, with conventional therapies often proving ineffective. While photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) with riboflavin/UV-A has shown success in treating bacterial and fungal keratitis, and PACK-CXL with rose bengal/green light has demonstrated promise in fungal keratitis, neither approach has been shown to effectively eradicate AK. This case study explores a novel combined same-session treatment approach using both riboflavin/UV-A and rose bengal/green light in a single procedure.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the long-term outcomes of scleral fixation of aniridic black diaphragm intraocular lenses (BDIOL) in 38 eyes affected by aniridia and aphakia due to trauma or congenital conditions.
  • After an average follow-up of 28 months, there was a significant improvement in visual acuity, and patients reported reduced glare and photophobia, though some experienced complications like elevated intraocular pressure and corneal decompensation.
  • The findings suggest that scleral fixation of BDIOL is an effective solution for patients lacking capsular support, providing good vision quality with a low rate of complications, regardless of prior surgical history.
View Article and Find Full Text PDF

Combination of Apigenin and Melatonin with nanostructured lipid carriers as anti-inflammatory ocular treatment.

Int J Pharm

December 2024

Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, 08028 Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN(2)UB), University of Barcelona, 08028 Barcelona, Spain. Electronic address:

Ocular inflammation is a complex pathology with limited treatment options. While traditional therapies have side effects, novel approaches, such as natural compounds like Apigenin (APG) and Melatonin (MEL) offer promising solutions. APG and MEL, in combination with nanostructured lipid carriers (NLC), may provide a synergistic effect in treating ocular inflammation, potentially improving patient outcomes and reducing adverse effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!